ACHN

Achillion to Report Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on February 20, 2013

[at noodls] – NEW HAVEN, Conn., Feb. 19, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to release fourth quarter and year-end 2012 financial results on Wednesday, … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion to Present at the 2013 Leerink Swann Global Healthcare Conference

[at noodls] – NEW HAVEN, Conn., Feb. 8, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Michael Kishbauch, President and Chief Executive Officer of Achillion, will present … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion to Present at the Noble Financial Capital Markets’ Ninth Annual Equity Conference

[at noodls] – NEW HAVEN, Conn., Jan. 17, 2013 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion Reports Interim Results on ACH-3102

[at noodls] – – Enrollment completed in pilot Phase 2a study of ACH-3102 and ribavirin for genotype 1b CC patients – – Up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is […]

As Competitors Pursue Alternatives Medgenics’ INFRADURE Gains Prominence for its Potential to Treat Hepatitis

[ACN Newswire] – Medgenics’ (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained production and delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboardSee who Achillion is hiring next, click here to view […]

Achillion to Present at Two Upcoming Investor Conferences

[at noodls] – NEW HAVEN, Conn., Nov. 30, 2012 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present at the following investor conferences … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Does Achillion Have a Place in the HCV Market of the Future?

[ACN Newswire] – By Ivan DeryuginThe biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation of drugs for a market stand to gain … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

Achillion to Present at Two Upcoming Investor Conferences

[at noodls] – NEW HAVEN, Conn., Nov. 13, 2012 (GLOBE NEWSWIRE) — Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present at the following investor conferences … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Lightweight Contender ACHN Declines on Gilead’s Latest Hepatitis Data

[ACN Newswire] – By Jake KingWith Gilead’s (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively at … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]

Achillion Provides Update on Clinical HCV Development Programs

[at noodls] – – Drug-Drug Interaction Study of Sovaprevir and ACH-3102 Completed – – ACH-2684, Second-Generation Protease-Inhibitor, Achieves Comparable Activity in Cirrhotic Versus Non-Cirrhotic Patients – – Posters … moreView todays social media effects on ACHNView the latest stocks trending across Twitter. Click to view dashboard […]